Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017

Synthetic Biologics,Inc.
Posted on: 27 Jul 17

PR Newswire

ROCKVILLE, Md., July 27, 2017

ROCKVILLE, Md., July 27, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights and financial results for the quarter ended June 30, 2017 on Thursday, August 3, 2017, and to host a conference call the same day at 8:30 a.m. EDT. The dial-in information for the call is as follows:

U.S. (toll free): 1-888-347-5280
International: +1 412-902-4280

Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be webcast over the Internet at https://www.webcaster4.com/Webcast/Page/1096/21899. An archived replay of the call will be available for approximately ninety (90) days at the same URL, https://www.webcaster4.com/Webcast/Page/1096/21899, beginning approximately one hour after the call's conclusion.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), pathogenic overgrowth and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.   

View original content with multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-report-second-quarter-2017-operational-highlights-and-financial-results-on-august-3-2017-300495037.html

SOURCE Synthetic Biologics, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 27/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.